Drug Delivery and Molecular Sensing (DDMS) Research Program Project Summary The Drug Delivery and Molecular Sensing (DDMS) Research Program aims to provide physical science/engineering and technology solutions to advance the understanding of cancer biology, and to improve prevention, detection and treatment of cancers. These solutions integrate Purdue Center for Cancer Research (PCCR) Foundational Disciplines into collaborative studies that are launched from DDMS-associated expertise, including molecular conjugates and nanoparticles for targeted drug delivery, new imaging modalities for surgical guidance and drug sensitivity, and new in vitro tumor models to study cancer biology. To accomplish future goals, the DDMS Program will pursue three scientific themes that are embodied in its specific aims.
Aim 1 : Next generation therapeutic delivery systems to precisely administer anti-cancer agents Aim 2: Ultra-precision sensing and imaging techniques and devices for early detection and prognosis Aim 3: Innovative enabling technologies for research across the cancer spectrum The program is comprised of 31 faculty members from 13 Purdue University academic departments. Members of the DDMS Program synergistically collaborate with other PCCR Research Programs, as demonstrated by strong inter-programmatic publications (20%). DDMS is highly productive, having generated 370 cancer-relevant publications between July 2015 and July 2019. Among these publications, 58% represent collaborative work. DDMS efforts are sustained by $4.6 million (direct) in peer-reviewed, cancer-relevant funding in the last budget year. In addition, 86 patents and five start-up companies were created. To facilitate this highly multidisciplinary Research Program, the Program Leaders (Drs. Bumsoo Han and Yoon Yeo) have been working on promoting collaborative research and integrating biological sciences and engineering disciplines. Notable outcomes of investigations during the current funding period are new nanoparticle formulations targeting both cancer and immune cells within the tumor microenvironment, ligand-targeted imaging and therapeutic agents, a new intraoperative image-guidance technique based on spectroscopy, and a new imaging modality to assess the chemosensitivity of tumor tissues. In addition, new in vitro tumor models have been developed to identify and validate new drug targets for pancreatic cancer and to perform research on drug resistance and tumor onset for breast cancer. During the next funding period, DDMS leadership will pursue four initiatives: (1) continued excellence in drug delivery and molecular sensing; (2) accelerated validation of sensing and imaging technologies with preclinical models; (3) building on computational and data science expertise for cancer biology and drug discovery; and (4) development of greater strength in physical science/engineering for oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023168-40
Application #
10024921
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-06-30
Support Year
40
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Purdue University
Department
Type
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Alpsoy, Aktan; Dykhuizen, Emily C (2018) Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes. J Biol Chem 293:3892-3903
Larocque, Elizabeth A; Naganna, N; Opoku-Temeng, Clement et al. (2018) Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase. ChemMedChem 13:1172-1180
Kumari, Rashmi; Silic, Martin R; Jones-Hall, Yava L et al. (2018) Identification of RECK as an evolutionarily conserved tumor suppressor gene for zebrafish malignant peripheral nerve sheath tumors. Oncotarget 9:23494-23504
VerHeul, Ross; Sweet, Craig; Thompson, David H (2018) Rapid and simple purification of elastin-like polypeptides directly from whole cells and cell lysates by organic solvent extraction. Biomater Sci 6:863-876
Poh, Scott; Chelvam, Venkatesh; Ayala-López, Wilfredo et al. (2018) Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases. Nanomedicine 14:1033-1043
Coleman, Rachel A; Trader, Darci J (2018) A Sensitive High-Throughput Screening Method for Identifying Small Molecule Stimulators of the Core Particle of the Proteasome. Curr Protoc Chem Biol 10:e52
AlAbdi, Lama; He, Ming; Yang, Qianyi et al. (2018) The transcription factor Vezf1 represses the expression of the antiangiogenic factor Cited2 in endothelial cells. J Biol Chem 293:11109-11118
Lee, Hyeong-Min; Clark, Ellen P; Kuijer, M Bram et al. (2018) Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome. Mol Autism 9:45
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Hall, Hana; Ma, Jingqun; Shekhar, Sudhanshu et al. (2018) Blue light induces a neuroprotective gene expression program in Drosophila photoreceptors. BMC Neurosci 19:43

Showing the most recent 10 out of 436 publications